Indications¹

Periodic fever syndromes
ILARIS® (canakinumab) is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

• Cryopyrin-associated periodic syndromes (CAPS), including:

  • Muckle-Wells syndrome (MWS)

  • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)

  • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash

• Tumour necrosis factor receptor associated periodic syndrome (TRAPS)

• Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)

• Familial Mediterranean Fever (FMF)

  • ILARIS should be given in combination with colchicine, if appropriate

Still’s disease
ILARIS is indicated in patients who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, for the treatment of active Still’s disease, including:

• Adult-onset Still’s disease (AOSD) 

• Systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older 

• ILARIS can be given as monotherapy or in combination with methotrexate 

Gouty arthritis
ILARIS is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom NSAIDs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.